8-K: Celcuity Raises $56.2 Million in Common Stock Offering to Fund Clinical Trials and Operations

Celcuity Inc. successfully closed a public offering of 3,871,000 shares of common stock, raising approximately $56.2 million in net proceeds to support working capital, research and development, and clinical trial expenditures.

Summary

• Celcuity Inc. has completed a public offering of 3,871,000 shares of common stock at a price of $15.50 per share.
• The offering closed on May 31, 2024, and generated net proceeds of approximately $56.2 million for the company after deducting underwriting discounts and other expenses.
• The company intends to use the funds for working capital, general corporate purposes, research and development, clinical trial expenses, and business development activities.
• A portion of the funds may be used to initiate a Phase 3 clinical trial evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as a first-line treatment for HR+/HER2advanced breast cancer.
• The company expects its existing cash, cash equivalents, short-term investments, and available borrowings, along with the net proceeds from this offering, will fund operations through at least the second half of 2026.

Sentiment

Score: 8

Explanation: The document reflects a positive sentiment due to the successful capital raise, which will enable the company to advance its clinical programs and extend its financial runway. The involvement of healthcare-focused investors further supports this positive outlook.

Positives

• The successful completion of the offering provides Celcuity with significant capital to advance its clinical programs.
• The company has secured funding to support operations through at least the second half of 2026, providing financial stability.
• The funds will support the initiation of a Phase 3 clinical trial for gedatolisib, a key therapeutic candidate.
• The offering attracted investments from several healthcare-focused investors, indicating confidence in the company's prospects.

Risks

• The company's future success depends on the outcome of its clinical trials, which are subject to inherent risks and uncertainties.
• Market conditions and other factors could impact the company's ability to achieve its goals.
• The company's financial performance is subject to risks outlined in its SEC filings.

Future Outlook

Celcuity expects that its existing cash, cash equivalents and short-term investments and available borrowings under its recently announced amended and restated loan and security agreement, together with the net proceeds from this offering, will be sufficient to fund Celcuity's operating expenses and capital expenditure requirements through at least the second half of 2026.

Industry Context

This capital raise is typical for a clinical-stage biotechnology company seeking to fund its research and development activities and advance its drug candidates through clinical trials. The involvement of healthcare-focused investors indicates a positive outlook for the company's prospects within the biotech industry.

Comparison to Industry Standards

• The size of the offering and the use of proceeds are consistent with industry norms for clinical-stage biotech companies.
• Comparable companies such as Xencor and Arcus Biosciences have also raised capital through public offerings to fund their clinical programs.
• The focus on a Phase 3 trial for a lead drug candidate is a common milestone for companies in this sector.
• The stated runway of funding through the second half of 2026 is a typical target for companies in this stage of development.

Stakeholder Impact

• Shareholders will see dilution of their ownership due to the issuance of new shares.
• Employees will benefit from the company's increased financial stability and ability to fund its operations.
• Customers and patients may benefit from the advancement of the company's clinical programs and potential new therapies.
• Creditors may view the company as a more stable borrower due to its increased cash reserves.
• Suppliers may benefit from increased business with the company.

Next Steps

• The company will use the net proceeds from the offering for working capital and general corporate purposes.
• The company plans to initiate a Phase 3 clinical trial to evaluate gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2advanced breast cancer.
• The company will continue to enroll patients in its ongoing Phase 3 and Phase 1b/2 clinical trials.

Key Dates

Keywords

common stock offering, capital raise, clinical trials, gedatolisib, breast cancer, biotechnology, oncology, working capital, research and development, financing